card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Immunotherapy and PD-L1: The Future of Precision Medicine

Advances in precision medicine lead to new trends in immunotherapy
Home / Insights / Immunotherapy and PD-L1: The Future of Precision Medicine

Advances in precision medicine have led to a paradigm shift for oncology research, from targeted therapies that rely largely on tyrosine kinase inhibitors (TKIs), to personalized therapy that demonstrate improvement in patient response along with considerably lower side effects. At the center of this shift is immunotherapy, in which researchers are developing drugs that harness the patient’s immune system to fight the cancer on its own.

Download this insight brief to explore recent advances in precision medicine, how immunotherapy works and the unique role of biomarker assays, such as PD-L1.

At IQVIA Laboratories, we help bring cutting-edge biomarker technologies and companion diagnostic assays to the forefront of clinical trial research in hope to identify biomarkers that can better predict patients that can respond to innovative drugs.

Authors:
Radha Krishnan MD, Chief Pathologist and Senior Medical Director
Patrice Hugo Ph.D., Chief Scientific Officer

Complete the form below to access this insight brief